Consists of Simeticone, Trimebutine
Pregnancy of Simeticone (Libertrim SII) in details
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).
Pregnancy of Trimebutine (Libertrim SII) in details
During pregnancy patients should avoid prolonged use of Trimebutine (Libertrim SII) Arika Healthcare because the risk of addiction in the fetus and the occurrence of withdrawal in the neonatal period.
If necessary using in lactation (breastfeeding) should be aware that tramadol in small amounts excreted in breast milk. In the case of long-term treatment can not been excluded the possibility of drug dependence.
Trimebutine (Libertrim SII) Arika Healthcare is not recommended for treatment of withdrawal syndrome drugs.
Patients need to avoid combination with MAO inhibitors.
During the period of treatment with Trimebutine (Libertrim SII) Arika Healthcare you should avoid to take alcohol.
Tramadol in the form of long-acting formulations should not be used in children under the age of 14 years.
During the period of tramadol using is not recommended to engage in activities that require special attention, speed of psychomotor reactions.
Reviews
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
